A5085805107- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuropeptides and Animal Physiology
- Sphingolipid Metabolism and Signaling
- Cancer Genomics and Diagnostics
- Liver Disease Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Gallbladder and Bile Duct Disorders
- Peptidase Inhibition and Analysis
- Pediatric Hepatobiliary Diseases and Treatments
- Genetic factors in colorectal cancer
- Antimicrobial Peptides and Activities
- Cell Adhesion Molecules Research
- Gut microbiota and health
- Chemokine receptors and signaling
- Proteoglycans and glycosaminoglycans research
- Soft tissue tumor case studies
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Sarcoma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
University Hospital Innsbruck
2004-2024
Universität Innsbruck
2005-2024
Innsbruck Medical University
2008-2024
Medizinische Hochschule Hannover
2024
University Hospital Frankfurt
2024
Goethe University Frankfurt
2024
University of Zurich
2022
Medical University of Vienna
2022
Kunming Medical University
2018
Ospedale di Bolzano
2007
Background: HCC is the leading cause of cancer in chronic liver disease. A growing body experimental mouse models supports notion that gut-resident and liver-resident microbes control hepatic immune responses and, thereby, crucially contribute to tumorigenesis. However, a comprehensive characterization intestinal microbiome fueling transition from disease humans currently missing. Methods: Here, we profiled fecal, blood, tissue patients with by 16S rRNA sequencing compared profiles...
Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently no prospective randomised head-to-head comparison between these treatments has yet been performed.We conducted a comparative propensity score (PS) analysis of overall (OS) progression-free survival (PFS) in tri-centre cohort patients with aPDAC undergoing palliative either GN or FOLFIRINOX.In unadjusted analysis, OS PFS were highly...
Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world insufficiently defined. purpose this study was to evaluate the a multi-center cohort (ELEVATOR) from Germany and Austria. Methods A retrospective data analysis 205 treated systemic at 14 different sites conducted. Overall survival, progression free overall response rate adverse event rates were assessed analyzed. Results...
Liver transplantation (LT) is potentially curative for patients with cirrhosis and hepatocellular carcinoma (HCC). However, this procedure usually reserved early tumor stages or after successful downstaging local regional therapies. In locally advanced HCC, current guidelines recommend locoregional palliative systemic therapies Barcelona Clinic Cancer (BCLC) B C, respectively.In article, we describe a 63-year-old male patient HCC (BCLC C) hepatitis C-associated cirrhosis. Following treatment...
The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance advanced pancreatic ductal adenocarcinoma (PDAC) not yet studied. In the present study we investigated AST/ALT as a possible predictor of treatment response and disease outcome patients with PDAC treated first-line gemcitabine/nab-paclitaxel.A post hoc analysis prospective, multicenter, noninterventional was...
Chronic inflammation is characterized by tissue infiltration with monocytes/macrophages, which possess broad proinflammatory, destructive, and remodeling capacities. Elevated levels of osteoprotegerin, an important regulator differentiation activation osteoclasts that also affects different cells the immune system, were found in serum patients chronic inflammatory diseases. The study whether osteoprotegerin monocyte locomotion vitro possible mechanisms pathways involved was investigated...
Background: Immunotherapy-based combinations are currently the standard of care in systemic treatment patients with HCC. Recent studies have reported unexpectedly long survival lenvatinib (LEN), supporting its use first-line for This study aims to compare real-world effectiveness LEN atezolizumab/bevacizumab (AZ/BV). Methods: A retrospective analysis was conducted evaluate and safety frontline AZ/BV or therapy advanced HCC across 18 university hospitals Europe. Results: The included 412...
Background and Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)–based systemic therapies is unclear. Approach Results: Retrospective study had CR according modified Response Evaluation Criteria in Solid Tumors (CR-mRECIST) ICI-based from 28 centers Asia, Europe, the United States. Of 3933 treated noncurative therapies, 174 (4.4%) CR-mRECIST, 97 (2.5%) RECISTv1.1 (CR-RECISTv1.1) as well. mean age total cohort (male, 85%;...
After an ischemic event vascular growth factors are involved in regulating leukocyte infiltration inflammatory processes. This study focused on effects of 2 other angiogenic factors, angiopoietin-1 and angiopoietin-2, human neutrophils the involvement angiopoietin receptor Tie-2.Neutrophils were from venous blood healthy donors cell migration was studied by micropore filter assays. Receptor expression investigated reverse transcriptase-polymerase chain reaction (PCR) for mRNA...
BackgroundPancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated activity (median overall survival [OS], 8.7 months) and tolerability in patients with metastatic PC (mPC). However, clinical evidence of nab-P/G elderly (>70 years), who account for majority mPC, is limited. This first prospective, multicentre, non-interventional study evaluating effectiveness younger (≤70 years) versus mPC daily...
In 2007, the ASSO-LM1 trial, a multicenter prospective study, was initiated to investigate resectability (R0) rate following preoperative combination therapy with XELOX and bevacizumab in patients potentially resectable colorectal liver metastases. Six cycles of systemic were administered preoperatively, although sixth cycle did not include bevacizumab, resulting 5 weeks between last dose surgery. Treatment plus restarted for another six postoperatively. total, 43 enrolled trial. Eight...
Background: Small cell neuroendocrine prostate cancer (SCNC) is a rare aggressive type of (NEPC) characterized by clinical course and lack response to hormone therapy. Case Description: We present case report 60-year-old man diagnosed with histologically confirmed primary metastatic (bone, lymph nodes visceral) SCNC small components an adenocarcinoma symptoms mimicking acute prostatitis. Of note, serum based markers (carcinoembryonic antigen, chromogranin A) were negative the patient had...
Accumulation of inflammatory mononuclear phagocytes in Alzheimer's senile plaques, a hallmark the innate immune response to beta-amyloid fibrils, can initiate and propagate neurodegeneration characteristic disease. Phagocytes migrate toward amyloid beta-protein involving formyl peptide receptor like-1-dependent signaling. Using human peripheral blood monocytes Boyden chamber micropore filter assays, we show that beta-protein- beta-precursor protein-induced migration was abrogated by...
Abstract Introduction Recent advances in prophylactic anticoagulation and antineoplastic treatment for advanced pancreatic cancer (aPC) warrant an updated reassessment of thromboembolic risk this population. This multicenter retrospective cohort study aims to comprehensively characterize incidence, factors, outcomes venous (VTE) arterial thromboembolism (ATE) homogenously treated patients with aPC. Methods Four hundred fifty-five aPC undergoing palliative first-line chemotherapy...
Increasing evidence shows the importance of platelet–endothelial cell interactions in progression atherosclerosis. Platelets contribute to coronary events both as major components thrombi and a triggering factor inflammation that leads plaque vulnerability. Recent data suggest statins, besides their lipid-lowering properties, exert pleiotropic effects may be beneficial Whether activated platelets influence cyclooxygenase-2 (COX-2) expression human umbilical vein endothelial cells (HUVEC),...
Summary In recent years there have been significant changes in the treatment of bile duct carcinoma. Immunotherapy has included first-line for about a year now (IO + cisplatin/gemcitabine). Cholangiocarcinomas are genetically very heterogeneous and several new targets identified years. These play an important role, especially second-line treatment. This review aims to highlight key milestones current with focus on targeted therapy options. Especially, data therapeutic options such as FGFR‑2,...
Importance International guidelines lack consistency in their recommendations regarding routine imaging the follow-up after pancreatic resection for ductal adenocarcinoma (PDAC). Consequently, strategies differ between centers worldwide. Objective To compare clinical outcomes, including recurrence-focused treatment and survival, patients with PDAC recurrence who received symptomatic or international affiliated European-African Hepato-Pancreato-Biliary Association (E-AHPBA). Design, Setting,...
Summary Colorectal cancer (CRC) is one of the most frequent entities worldwide and a leading cause death. The disease known to develop from potentially curable, premalignant lesions over several years therefore suitable for screening procedures preventive measures. Several trials have demonstrated reduced incidence mortality in cohorts. A multitude different strategies CRC been implemented parts world. While randomized controlled studies directly comparing are still ongoing, colonoscopy...